Immunometabolism Drug Development Summit

Immunometabolism Drug Development Summit

Hanson Wade 12/02/2019 to 13/02/2019 | USA, The Colonnade Boston Hotel, 120 Huntington Avenue, Boston, 02116
+1 6174554188

As scientific breakthroughs and novel discoveries reveal the causal link and interface between metabolic pathways and immune cell function, the inaugural Immunometabolism Drug Development Summit 2019 is dedicated to help large pharma, biotech and academia translate basic immunometabolism research into a novel class of clinically safe and effective therapeutics for immune-mediated diseases.

The field of immunometabolism has thrived over the last decade, revealing not only a better understanding of immune cells and their functions but also the impact of key metabolic pathways on immune cell development, fate, and behavior. As such the emerging field of immunometabolism offers a tremendous opportunity to set a higher standard for how immune-mediated diseases are treated.

http://www.immunometabolismdrugdev.com/

Contact:info@hansonwade.com+ 1 617 455 4188

URLs:

Brochure: https://go.evvnt.com/304815-0?pid=5657 

Tickets: https://go.evvnt.com/304815-1?pid=5657 

 

Time: 8:00 am to 4:00 pm

Prices:

Drug Developer and Solution Provider Earlybird Conference + 1 Workshop (Book by 09/11/18): USD 1798.0,

Drug Developer and Solution Provider Conference + 1 Workshop (standard rate) : USD 2398.0,

Academic, Not-for-Profit and Start-up* Earlybird Conference + 1 Workshop (Book by 09/11/18): USD 1298.0,

Academic, Not-for-Profit and Start-up* Conference + 1 Workshop (standard rate): USD 1898.0,

Drug Developer and Solution Provider Conference Only Earlybird (Book by 09/11/18): USD 1399.0,

Drug Developer and Solution Provider Conference Only (standard rate): USD 1999.0,

Academic, Not-for-Profit and Start-up* Conference Only Earlybird (Book by 09/11/18): USD 899.0,

Academic, Not-for-Profit and Start-up* Conference Only (standard rate): USD 1499.0

Speakers: Laurence Turka (Rheos Medicines), Robert Wild (Dracen Pharmaceuticals), Paul-Peter Tak (Levicept and Sitryx Therapeutics), Lauriane Cabon (Roche), Mateusz Nowak (Selvita)

 

more
page up